KR100700481B1 - Composition comprising the extract of Cinnamomum cassia for preventing and treating fracture - Google Patents

Abstract

A pharmaceutical composition comprising an extract of Cinnamomum cassia is provided to show excellent angiogenesis promoting activity by vascular cell proliferation, movement, differentiation and secretion promoting of growth factor, proliferation and differentiation promoting of osteoblast, alkali phosphatase(ALP) activity promoting, vascular endothelial growth factor(VEGF) secretion promoting and vascular endothelial growth factor receptor(VEGF R1) activity promoting function, thereby being usefully used for treating and preventing fracture. The pharmaceutical composition for preventing and treating fracture comprises an extract of Cinnamomum cassia as an effective ingredient and shows the bone fusion effect due to angiogenesis and osteoblast proliferation activity of the extract of Cinnamomum cassia. The extract is prepared by using a solvent selected from the group consisting of water, C1-4 alcohol and a mixture solvent thereof.

Description

Composition comprising the extract of Cinnamomum cassia for preventing and treating fracture}

1 is a diagram showing the degree of survival of osteoblasts (Saos-2) when treated with gage extract,

Figure 2 is a diagram showing the degree of alkaline phosphatase (ALP) activity when treated with gage extract,

Figure 3 is a diagram showing the secretion activity of angiogenesis factor (VEGF) in osteoblasts (Saos-2) when treated with the extract

Figure 4 is a diagram showing the expression level of VEGF, VEGF R1, OCN, OPN, and Col I gene in osteoblasts (Saos-2) when treated with gage extract,

Figure 5 is a diagram showing the survival of osteoblasts (Saos-2) when treated with cinnamic acid, an effective active indicator of the gage,

Figure 6 is a diagram showing the degree of alkaline phosphatase (ALP) activity in the treatment of cinnamic acid, an effective indicator of the active material.

The present invention relates to a composition for the treatment and prevention of fractures containing Cinnamomum cassia extract having an angiogenic and osteoblast proliferation effect.

Angiogenesis is a series of processes in which new blood vessels are made from existing blood vessels, invading through the extracellular matrix (ECM), which is the migration of endothelial cells that make up blood vessels and the intercellular barrier. It is known to be precisely regulated by the balance between inducers and inhibitors through the stages of invasion, proliferation, and tube-like formation of blood vessels (Schott RJ and Morrow LA). , Cardiovasc.Res., 27 (7), pp 1155-1161, 1993). This is a highly regulated process and rarely occurs under normal conditions except for wound healing and the development of embryos or corpus luteum (Folkman J and Shing Y, J. Biol. Chem. , 267 (16), pp10931-10934, 1992). Overall angiogenesis is associated with several steps that begin with the degradation of enzymes in the associated basement membrane. In addition, angiogenesis includes platelet-derived growth factor, bone morphogenic protein-2 (BMP-2), vascular endothelial growth factor (VEGF), and Proper stimulation by angiogenic factors such as basic fibroblast growth factor (bFGF) and FGF-2 is required (Folkman J and Shing Y, J. Biol. Chem. , 267 (16), pp10931-10934, 1992; Ferrara N, Recent Prog.Horm . Res. , 55, pp 15-35, 2000; Burgess WT and Maciag T, Annu. Rev. Biochem. , 58, pp575-606, 1989).

The importance of angiogenesis in the musculoskeletal system, which is relatively affected by the blood supply, has led to the emergence of therapeutic angiogenesis, and the promotion of angiogenesis in bone union, bone formation, bone graft, and ischemic bone necrosis has already helped the treatment. It has been known to be used for giving (Ahn Jae-hoon et al., Journal of the Korean Orthopedic Surgeon , 34, pp631-642, 1999). A cytokine that increases permeation of plasma proteins in capillaries, which promotes cell division and migration, maintains the survival of newly formed blood vessels by inhibiting cell death, and promotes the migration of new cells VEGF, which promotes development and differentiation, has recently focused on a role in the regulation of bone growth and has been reported to have a stronger inducer of osteoblast proliferation than BMP-2 (Midy V and Plouet J, Biochem Biophys Res Commun., 199 (1), pp 380-386, 1994). It has also been reported that statins promote the expression of bone assimilation elements such as VEGF and BMP-2, thereby promoting the proliferation and calcification of osteoblasts (Maeda T. et al., Endocrinology , 144 (2), pp 681-692, 2003).

Bone is a specialized tissue that combines a hardened calcified surface with an internal cellular component called the bone marrow. The combination of these two physiologically different structures is due to the lifelong bone remodeling process, which causes osteoclasts in the bone marrow It is explained by bone resorption that gathers and destroys bone as it scavenges to the surface and bone formation by osteoblasts gathered at the site where absorption occurs (Park JS, Natl. Nutr. , 215, pp 25-31, 2000).

Osteoblasts located on the bone surface have alkaline phosphatase (ALP), a glycoprotein enzyme in the cell membrane, and collagen type I (col I), osteocalcin (OCN; osteocalcin), and osteopontin (OPN; osteopontin). ), Secreting and calcifying bone matrix substances such as bone sialoprotein (BSP) (Collier FM et al., Endocrinology, 139 (3), pp1258-1267, 1998).

The medicines commonly used for arthritis, fractures, and osteoporosis cause systemic side effects such as digestive disorders, gastrointestinal disorders, and decreased kidney function. Systemic administration over time poses many problems. Therefore, there is a need for a new prescription that has excellent effects in the treatment of fractures and bone regeneration, minimizes side effects, and has excellent joint tissue protection effect.

Cinnamomum cassia A young branch of cassia (or cinnamon), an evergreen arboretum of the feldspar family, spicy, sweet and warm in nature, acting on the heart, lungs and bladder. It is known to strengthen the stomach, suppress paralysis, have analgesic and cardiovascular effects, expand the blood vessels of the skin and stimulate sweat glands to cause sweating, antipyretic effect, and inhibit the virus. Chills, fever, headache, body pain It is used for sweating or palpitations. Long columnar, many branches, 30-70cm long, 0.3-1cm thick. The surface is reddish brown or brown with vertical ridges and traces of fine wrinkles and small lumps of leaves and branches. The quality is solid, brittle and easy to cut, Guangxi and Guangdong provinces are mainly produced. Vietnam, Sri Lanka It is also grown in India. As a result of the pharmacological experiments of gages, sweating, antipyretic, analgesic, cardiopulmonary, antiallergic, antiviral and antifungal effects have been found. It is not disclosed.

Therefore, the inventors of the present invention is an excellent angiogenesis-promoting effect and osteoblast proliferation By confirming that the bone union effect, the present invention was completed.

The present invention is to provide a pharmaceutical composition and health functional food useful for the prevention and treatment of fractures containing the gage extract with excellent angiogenesis promoting effect and osteointegration effect by osteoblast proliferation.

In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention and treatment of fractures containing Cinnamomum cassia extract as an active ingredient.

The extract is characterized in that the bone union effect due to the formation of blood vessels and osteoblast proliferation.

In addition, the extract is water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, preferably an extract available in a mixed solvent of ethanol and water, preferably water or a mixing ratio of 1: 0.2 to 1: 5 (v / v Extracts soluble in a mixed solvent of water and ethanol).

Hereinafter, the present invention will be described in detail.

Cage extract of the present invention can be obtained as follows.

About 1 to 20 times, preferably about 5 to 15 times the amount of water, ethanol, methanol or the like, lower alcohols of C ₁ to C ₄ or about 1: 0.1 to 1: 10, preferably a mixed solvent of water and ethanol having a mixing ratio (v / v) of 1: 0.2 to 1: 5, stirred extraction at room temperature for about 0.5 to 48 hours, preferably 1 to 30 hours, hot water extraction By using an extraction method such as cold extraction, room temperature extraction, reflux cooling extraction or ultrasonic extraction, the extraction solution obtained after extraction at room temperature is preferably filtered, concentrated under reduced pressure or dried to obtain the lock extract of the present invention.

Cage extract of the present invention obtained by the above manufacturing process is osteoblasts by the proliferation of Saos-2 cells, osteoblasts, increased alkaline phosphatase (ALP) activity, promoting the secretion of vascular endothelial growth factor and increasing the activity of vascular endothelial growth factor receptor Cell proliferation effect was shown to have a bone union activity to prevent and treat fractures.

The present invention provides a pharmaceutical composition for the prevention and treatment of fractures containing the ginseng extract obtained by the above manufacturing process as an active ingredient.

Cage extract of the present invention has little toxicity and side effects, so can be used with confidence even for prolonged administration for prophylactic purposes.

Fracture preventing and treating compositions of the present invention, the total weight of the composition comprises 0.1 to 50% by weight of the gage extract.

The pharmaceutical composition comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.

Pharmaceutical compositions comprising the extract of the present invention in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, suppositories, and sterile injectable solutions, respectively, according to a conventional method. Can be formulated and used. Carriers, excipients and diluents which may be included in the composition comprising the extract of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate , Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations include at least one excipient such as starch, calcium carbonate, sucrose in the extract. Or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The preferred dosage of the gage extract of the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 100 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.

Cage extract of the present invention can be administered to various mammals such as mice, mice, livestock, humans. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

The present invention also provides a dietary supplement for the prevention and improvement of fractures containing Cinnamomum cassia extract as an active ingredient exhibiting bone union effect due to angiogenesis and osteoblast proliferation.

As defined herein, "health functional food" means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to Act No. 6767 of the Health Functional Food Act, and "functional" means It means ingestion for the purpose of obtaining useful effects on health use such as nutrient control or physiological action on structure and function.

Foods to which the extract can be added include, for example, various foods, beverages, gums, teas, vitamin complexes, health functional foods, powders, granules, tablets, capsules or beverages.

It may also be added to foods or beverages for the purpose of preventing and treating fractures. At this time, the amount of the extract in the food or beverage may be added in 0.01 to 15% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml. have.

The health functional beverage composition of the present invention is not particularly limited to other ingredients except for containing the cinnamon extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention. Flavoring agents such as flavoring agents and natural flavoring agents, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, Alcohols, carbonation agents used in carbonated drinks, etc. The extract of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. The components may be used independently or in combination The ratio of such additives is not so critical but is usually selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.

Hereinafter, the present invention will be described in detail by the following Examples and Experimental Examples.

However, the following Examples and Experimental Examples are only illustrative of the present invention, and the content of the present invention is not limited by the following Experimental Examples.

Example 1 Preparation of Cinnamon Extract

It was purchased from Kyunghee Medical Center Oriental Medicine Hospital, washed with water, and removed the contaminants. Then, 2 g of 50% (v / v) ethanol aqueous solution was added to 250 g of a well-dried cage, and refluxed for 6 hours while stirring. The filtrate was collected and the residue was added to 1.5 L of 30% (v / v) ethanol aqueous solution and re-extracted for 3 hours, and the filtrates were combined and concentrated to 1.5 L. The same amount of saturated n-butyl alcohol was added thereto, and the layers were separated three times. Then, only n-butyl alcohol soluble layer was collected and concentrated under reduced pressure until the extract was dried at 58 ° C. 0.2-L water was added to the state that n-butyl alcohol and water were almost evaporated, and then azeotropically concentrated. Then, the mixture was repeatedly concentrated under reduced pressure. Finally, the same amount of distilled water was added and suspended, followed by freeze-drying. : 8.1%).

Reference Example 1. Osteoblast Culture

Saos-2 cells (ATCC Accession No .; HTB-85), a human-derived osteoblast-like cell line, were obtained from the American Type Culture Collection, USA (ATCC) and 15% fetal bovine serum (FBS). Culture was performed using medium (McCoy's 5A, Gibco BRL, USA) to which% penicillin / streptomycin (Invitrogen Corporation, CA, USA) was added.

Reference Example 2 Reverse Transcription Polymerase Chain Reaction (RT-PCR)

RNA was prepared using Trizol reagent (TRIzol reagent, Invitrogen Corporation, CA, USA). Reverse transcription by adding buffer to 1 μg total RNA, Oligo (dT) ₁₂ primer, dNTP (10 mM), 0.1M dithiothritol (DTT, dithiotreitol), reverse transcriptase (Promega, USA) and RNase inhibitor The reaction was carried out at 42 ° C. for 60 minutes. Polymerase Chain Reaction (PCR) using each of the cDNAs synthesized above and the primers described in Table 1 and SEQ ID NOs: 1 to 12 was 0.5 μg of cDNA and 2.5 units of Taq polymerase (TaKaRa Taq ^™ , Takara). , Japan), 1.5 mM dNTP, 1x buffer (10 mM Tris-HCl pH 8.3, 50 mM KCl, 0.1% Triton X-100), 20 pmol of each pair of primers were added, the total volume was adjusted to 10 μl with distilled water, TaKaRa Biotechnology, Seoul, Korea). The product produced by PCR was subjected to electrophoresis on 1.8% agarose gel and stained with EtBr (ethidium bromide) to identify a specific band. Beta-actin (β-Actin), a PCR product using primers of SEQ ID NOs: 1 and 2, was used as an indicator gene and quantified using Gel-Doc EQ (BIO-RAD Laboratories, Milan, Italy).

gene Sequence of primer β-Actin Forward direction 5´CCTGGCCAAGGTCATCCATGACAACTTTGG3´ Reverse 5´CATGAGGTCCACCACCCTGTTGCTGTAGCC3´ OCN Forward direction 5´GAGGACCCTCTCTCTGCTCACTCTGCTGGC3´ Reverse 5´GTGGTGCCATAGATGCGCTTGTAGGCGTCC3´ OPN Forward direction 5´CTCGGATGAATCTGACGAATCTCACCATTC3´ Reverse 5´CTTACTCTTAGGGTCTAGGACTAGCTTGTC3´ Col1 Forward direction 5´TGGTCTTGGAGGAAACTTTGC3´ Reverse 5´AGTATCTCCTTTGGCACCATC3´ VEGF Forward direction 5´TGCACCCACGACAGAAGGGGA3´ Reverse 5´TCACCGCCTTGGCTTGTCACAT3´ VEGF R1 Forward direction 5'-CAGCCATGAATTTCACAGCC-3 ' Reverse 5'-GGGAGTTTCCATGAAGCCAC-3 '

Experimental Example 1. Measurement of osteoblast growth promoting activity of the extract in vitro )

The effect of the extract on the proliferation of osteoblasts was measured using the WST-8 assay (cell counting kit-8, Dojindo molecular technologies, Tokyo, Japan). After dispensing osteoblast-like cells, Saos-2 cells in 96-well plates at a concentration of 1 × 10 ⁴ cells / well, the extract of Example 1 was prepared by concentration (0.01, 0,1, 1, 10, 100 ㎍ / ㎖) was added 100 ㎕ each and incubated for 72 hours. 10 μl WST-8 (water-soluble tetrazolium salt; 2- (2-methoxy-4-nitrophenyl) -3- (4-nitrophenyl) -5- (2,4-disulfophenyl) -2H-tetrazolium, monosodium salt) After addition and incubation for 2 hours, when WST-8 formazan was formed and developed, the absorbance was measured and measured at 450 nm using an ELISA reader. Cell viability is shown in Figure 1 measured by the percentage of absorbance of the sample treated group compared to the control.

As shown in FIG. 1, the extract was not affected the survival rate of Saos-2 cells for 3 days in the range of 0-100 ㎍ / ㎖ concentration, it was confirmed that it is a safe drug without cytotoxicity, It was confirmed that Saos-2 cell survival was significantly increased at concentrations of 0.1 and 10 μg / ml.

Experimental Example 2 Determination of Activity of Alkali Phosphatase (ALP)

The serum enzyme alkaline phosphatase (ALP) is an enzyme that is an indicator of bone formation and is produced during the differentiation of osteoblasts (Zhao Y et al., Biol. Pharm. Bull. , 28 (8), pp1371-1376 , 2005). ALP activity was measured to determine whether the extract in the osteoblast differentiation in osteoblast differentiation.

ALP activity is the degree to which ALP decomposes and develops para-nitrophenylphosphate (pNPP; p-nitrophenylphosphate) into para-nitrophenol and phosphate. , MO, USA). Saos-2 cells, which are osteoblast-like cells prepared and treated as in Experimental Example 1, were lysed with 0.1% Triton X-100 (Triton X-100, Sigma, USA), and an ultrasonic machine (Branson, USA) and centrifuged at 12,000 g, 4 ° C for 10 minutes. The supernatant was incubated with reaction buffer at 37 ° C. for 3 minutes, and then the reaction was stopped using 0.1 N NaOH. The absorbance was measured at 405 nm. The standard line was quantified using para-nitrophenol (Sigma-Aldrich Co., MO, USA), and based on this, the ALP amount of the sample was converted.

Experimental results As shown in Figure 2, after three days of treatment to osteoblasts, the gage extract of the present invention was confirmed to exhibit excellent ALP activity at 0.01 and 1 ㎍ / ㎖, gage extract promotes osteoblast differentiation I could see.

Experimental Example 3. Measurement of secretion and activity of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGF R1)

Vascular endothelial growth factor (VEGF) is an angiogenesis-promoting factor synthesized by cells late in the differentiation of osteoblast-like cells, Saos-2 cells. In order to determine the effect on the experiment was carried out as follows.

In a 48-well plate, osteoblast-like cell line Saos-2 was cultured by dispensing at a concentration of 1 × 10 ⁴ cells / well, and then, each extract was prepared by concentration (0-100 μg / ml). And incubated for 72 hours.

3-1. Determination of VEGF Secretion Promoting Activity of Cajun Extract

In order to quantify VEGF expression, the cell culture solution was collected and stored at -70 ° C. VEGF quantification was performed using an ELISA kit (VEGF ELISA kit, R & D systems INC., MN, USA). 100 μl of the culture was reacted on a plate of an antibody-labeled kit, and the reaction solution was washed with phosphate buffer (PBS) and peroxidase-attached goat anti-mouse immunoglobulin G (peroxidase-labelled goat anti-mouse IgG, R & D). systems INC., MN, USA) and washed again. Color was developed using a substrate (TMB; 3,3 ', 5,5'-tetramethylbenzidine) and the reaction was terminated. The absorbance at 450 nm was measured using an ELISA reader, and the results are shown in FIG. 3.

Experimental results, as shown in Figure 3, the gage extract of the present invention was confirmed to increase the VEGF secretion, an angiogenesis-promoting factor, especially at low concentrations significantly increase the secretion of VEGF by the gage extract promotes blood vessel production Could confirm.

3-2. Determination of VEGF and VEGF R1 Gene Expression Promoting Activity

VEGF and VEGF R1 of Saos-2 Cells, Osteoblast-like Cell Lines Treated with Gage Extract Using Reverse Transcription Polymerase Chain Reaction (RT-PCR) of Reference Example 2 Vascular endothelial growth factor receptor 1) gene expression was evaluated.

As shown in FIG. 4, after 7 days of culture, VEGF and VEGF R1 gene expression was increased depending on the concentration of 0.1, 10 μg / ml of the extract. In other words, it can be seen from the above results that the extract extract promotes growth factor production and promotes the activity of osteogenic differentiation gene.

Experimental Example 4. Measurement of gene expression promoting activity related to bone formation

Osteocalcin (OCN), Osteopontin (OPN) and Collagen I (Col I; type Icollagen) are secreted from osteoblasts and the activity of OCN, OPN, and Col I is a determinant of osteoblast proliferation. Increasing its concentration suggests that osteoblast growth and differentiation is active (Collier FM et al ,, Endocrinology, 139 (3), pp1258-1267, 1998). In order to determine whether the administration of the extract of the present invention affects the activity of OCN, OPN, Col I was performed as follows.

In a 48-well plate, osteoblast-like cell line Saos-2 was cultured by dispensing at a concentration of 1 × 10 ⁴ cells / well, and then treated with 1 μg / ml of stopper extract in each well for 14 days. Incubated. Cultures were exchanged every 3 days, cultures were collected on day 3 to measure the secretion activity of collagen type I, and RNA was extracted from cells on days 3, 7, and 14 to express OCN, OPN and Col I genes. Was analyzed by RT-PCR.

As a result, the expression of OCN, OPN, and Col I genes increased as shown in FIG. In other words, it can be seen from the above results that the extract extract promotes growth factor production and promotes the activity of osteogenic differentiation gene.

Experimental Example 5. Measurement of osteoblast proliferation of effective active indicator substance Cinnamic acid

Saos-2 cells, osteoblast-like cells, were dispensed in 96-well plates at a concentration of 1 × 10 ⁴ cells / well, and then the indicators were searched to determine whether the indicators were active. After HPLC analysis, it was confirmed that it was cinnamic acid, and purchased (purchased) cinnamic acid (0.01, 0,1, 1, 10, 100 μg / ml) was added to 100 μl and incubated for 72 hours. . 10 μl of WST-8 (water-soluble tetrazolium salt; 2- (2-methoxy-4-nitrophenyl) -3- (4-nitrophenyl) -5- (2,4-disulfophenyl) -2H-tetrazolium, monosodium salt) After addition and incubation for 2 hours, when WST-8 formazan was formed and developed, it was quantified by measuring absorbance at 450 nm using an ELISA reader. Cell viability is shown in Figure 5 measured by the percentage of absorbance of the sample treated group compared to the control.

As shown in FIG. 5, the survival rate of Saos-2 cells was not affected for 3 days in the range of 0-100 ㎍ / ml cinnamic acid isolated from the basin, thus confirming that it was a safe drug without cytotoxicity. It was also confirmed that significantly increased Saos-2 cell survival at concentrations of 0.01 and 100 μg / ml.

Experimental Example 6. Measurement of Alkali Phosphatase (ALP) Activity of Cinnamic Acid

The serum enzyme alkaline phosphatase (ALP) is an enzyme that is an indicator of bone formation and is produced during the differentiation of osteoblasts (Zhao Y et al., Biol. Pharm. Bull. , 28 (8), pp1371-1376 , 2005). ALP activity was measured to determine whether cinnamic acid isolated from the basin had a different effect on osteoblast differentiation.

ALP activity is the degree to which ALP decomposes and develops para-nitrophenylphosphate (pNPP; p-nitrophenylphosphate) into para-nitrophenol and phosphate. , MO, USA). Saos-2 cells, which are osteoblast-like cells prepared and treated as in Experimental Example 5, were lysed with 0.1% Triton X-100 (Triton X-100, Sigma, USA), and an ultrasonic machine (Branson, USA) and centrifuged at 12,000 g, 4 ° C for 10 minutes. The supernatant was incubated with reaction buffer at 37 ° C. for 3 minutes, and then the reaction was stopped using 0.1 N NaOH. The absorbance was measured at 405 nm. The standard line was quantified using para-nitrophenol (Sigma-Aldrich Co., MO, USA), and based on this, the ALP amount of the sample was converted.

Experimental results, as shown in Figure 6, cinnamic acid isolated from the basin of the present invention 3 days after the treatment to osteoblasts, it was confirmed that the excellent ALP activity at 0.01 to 100 ㎍ / ㎖, differentiation of osteoblasts It was found to promote.

Experimental Example 7 Repeated Oral Toxicity Test in Rats

Repeated dose toxicity experiments were performed using 6-week-old SPF SD rats as follows.

Six animals per group were suspended orally administered in a 0.5% methylcellulose solution in the extract of Example 1 orally once a day for 2 weeks at a dose of 2 g / kg. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed. Necropsy was performed to observe abdominal and thoracic organ abnormalities.

As a result, no significant clinical symptoms or dead animals were noted in all animals treated with the test substance, and no toxic changes were observed in weight changes, blood tests, blood biochemical tests, and autopsy findings. Therefore, the ginseng extract according to the present invention did not show a change in toxicity in all rats up to 2000 mg / kg and the minimum lethal dose (LD ₅₀ ) orally administered was determined to be a safe substance more than 2000 mg / kg.

Hereinafter, an example of the preparation of a pharmaceutical composition containing the extract of the present invention will be described, but the present invention is not intended to limit the present invention but is only intended to be described in detail.

Formulation Example 1 Preparation of Powder

Cinnamon Extract 20 mg

Lactose 100 mg

Talc 10 mg

The above ingredients are mixed and filled in an airtight cloth to prepare a powder.

Formulation Example 2 Preparation of Tablet

Cage Extract 10 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.

Formulation Example 3 Preparation of Capsule

Cage Extract 10 mg

3 mg of crystalline cellulose

Lactose 14.8 mg

Magnesium Stearate 0.2 mg

According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.

Formulation Example 4 Preparation of Injection

Cage Extract 10 mg

Mannitol 180 mg

Sterile distilled water for injection 2974 mg

Na ₂ HPO ₄ , 12H ₂ O 26 mg

According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).

Formulation Example 5 Preparation of Liquid

Cinnamon Extract 20 mg

10 g of isomerized sugar

5 g of mannitol

Purified water

According to the conventional method of preparing a liquid solution, each component is added and dissolved in purified water, lemon flavor is added to the mixture, and then the above ingredients are mixed, purified water is added to adjust the total amount to 100 ml, and then filled in a brown bottle. The solution is prepared by sterilization.

Formulation Example 6 Preparation of Healthy Food

Cinnamon Extract 1000 mg

Vitamin mixture proper amount

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

Vitamin B6 0.5 mg

0.2 μg of vitamin B12

Vitamin C 10 mg

10 μg biotin

Nicotinic Acid 1.7 mg

Folate 50 ㎍

Calcium Pantothenate 0.5mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.

Formulation Example 7 Preparation of Healthy Drink

Cinnamon Extract 1000 mg

Citric acid 1000 mg

100 g oligosaccharides

Plum concentrate 2 g

1 g of taurine

Add 900 ml of purified water

After mixing the above components in accordance with the conventional healthy beverage manufacturing method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and refrigerated Used to prepare the healthy beverage composition of the invention.

Although the composition ratio is mixed with a relatively suitable component for a preferred beverage in a preferred embodiment, the compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

Cage extract according to the present invention exhibits angiogenesis-promoting activity by promoting vascular cell proliferation, migration, differentiation and growth of secretion of growth factors, promotes proliferation and differentiation of osteoblasts, promotes alkaline phosphatase (ALP) activity, vascular endothelial growth factor (VEGF) Since it has a secretion promoting and vascular endothelial growth factor receptor (VEGF R1) activity promoting activity, it can be useful as a pharmaceutical composition and health functional food for the prevention and treatment of fractures.

Attach sequence list electronic file

Claims (5)

A pharmaceutical composition for the prevention and treatment of fractures containing Cinnamomum cassia extract as an active ingredient. According to claim 1, wherein the extract is a pharmaceutical composition, characterized in that the bone union effect by the formation of blood vessels and osteoblast proliferation. The pharmaceutical composition according to claim 1, wherein the extract is an extract available in a solvent selected from water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. Health functional food for the prevention and improvement of fractures containing Cinnamomum cassia extract as an active ingredient, showing bone union effect by angiogenesis and osteoblast proliferation.  The health functional product of claim 4 in the form of a powder, granule, tablet, capsule or beverage.

Images